Literature DB >> 18481174

Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS).

Johannes Brettschneider1, Helga Mogel, Vera Lehmensiek, Tino Ahlert, Sigurd Süssmuth, Albert C Ludolph, Hayrettin Tumani.   

Abstract

Cerebrospinal fluid (CSF) is a promising source of biomarkers in amyotrophic lateral sclerosis (ALS). Using the two-dimensional difference in gel electrophoresis (2-D-DIGE), we compared CSF samples from patients with ALS (n = 14) with those from normal controls (n = 14). Protein spots that showed significant differences between patients and controls were selected for further analysis by MALDI-TOF mass spectrometry. For validation of identified spots western blot analysis and ELISA was performed. We identified 2 proteins that were upregulated and 3 proteins that were down-regulated in CSF in ALS. Of these, two proteins (Zn-alpha-2-glycoprotein and ceruloplasmin precursor protein) have not been reported in CSF of patients with ALS so far. In contrast, several other proteins (transferrin, alpha-1-antitrypsin precursor and beta-2-microglobulin) seem to be unspecifically affected in different neurological diseases and may therefore be of limited value as disease-related biochemical markers in ALS. Further evaluation of the candidate proteins identified here is necessary.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18481174     DOI: 10.1007/s11064-008-9742-5

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  20 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  Cerebrospinal fluid proteome profile in multiple sclerosis.

Authors:  V Lehmensiek; S D Süssmuth; G Tauscher; J Brettschneider; S Felk; F Gillardon; H Tumani
Journal:  Mult Scler       Date:  2007-08       Impact factor: 6.312

3.  Cerebrospinal fluid protein reactions during non-neurological surgery.

Authors:  R Anckarsäter; N Vasic; L Jidéus; M Kristiansson; H Zetterberg; K Blennow; H Anckarsäter
Journal:  Acta Neurol Scand       Date:  2007-04       Impact factor: 3.209

Review 4.  Biomarkers for amyotrophic lateral sclerosis.

Authors:  Robert Bowser; Merit Cudkowicz; Rima Kaddurah-Daouk
Journal:  Expert Rev Mol Diagn       Date:  2006-05       Impact factor: 5.225

5.  LC-MS/MS quantification of Zn-alpha2 glycoprotein: a potential serum biomarker for prostate cancer.

Authors:  Olga P Bondar; David R Barnidge; Eric W Klee; Brian J Davis; George G Klee
Journal:  Clin Chem       Date:  2007-02-22       Impact factor: 8.327

6.  Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase.

Authors:  H X Deng; A Hentati; J A Tainer; Z Iqbal; A Cayabyab; W Y Hung; E D Getzoff; P Hu; B Herzfeldt; R P Roos
Journal:  Science       Date:  1993-08-20       Impact factor: 47.728

7.  Identification of potential CSF biomarkers in ALS.

Authors:  G M Pasinetti; L H Ungar; D J Lange; S Yemul; H Deng; X Yuan; R H Brown; M E Cudkowicz; K Newhall; E Peskind; S Marcus; L Ho
Journal:  Neurology       Date:  2006-02-15       Impact factor: 9.910

8.  Proteomic analysis of multiple sclerosis cerebrospinal fluid.

Authors:  B N Hammack; K Y C Fung; S W Hunsucker; M W Duncan; M P Burgoon; G P Owens; D H Gilden
Journal:  Mult Scler       Date:  2004-06       Impact factor: 6.312

9.  Proteome analysis of cerebrospinal fluid in Guillain-Barré syndrome (GBS).

Authors:  V Lehmensiek; S D Süssmuth; J Brettschneider; G Tauscher; S Felk; F Gillardon; H Tumani
Journal:  J Neuroimmunol       Date:  2007-03-26       Impact factor: 3.478

10.  A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease.

Authors:  Odile Carrette; Isabelle Demalte; Alexander Scherl; Oezkarn Yalkinoglu; Garry Corthals; Pierre Burkhard; Denis F Hochstrasser; Jean-Charles Sanchez
Journal:  Proteomics       Date:  2003-08       Impact factor: 3.984

View more
  15 in total

1.  Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics.

Authors:  Henrik Ryberg; Jiyan An; Samuel Darko; Jonathan Llyle Lustgarten; Matt Jaffa; Vanathi Gopalakrishnan; David Lacomis; Merit Cudkowicz; Robert Bowser
Journal:  Muscle Nerve       Date:  2010-07       Impact factor: 3.217

Review 2.  On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia.

Authors:  F Geser; D Prvulovic; L O'Dwyer; O Hardiman; P Bede; A L W Bokde; J Q Trojanowski; H Hampel
Journal:  Prog Neurobiol       Date:  2011-09-03       Impact factor: 11.685

Review 3.  Expression and Function of Zinc-α2-Glycoprotein.

Authors:  Xin Wei; Xi Liu; Changhong Tan; Lijuan Mo; Hui Wang; Xi Peng; Fen Deng; Lifeng Chen
Journal:  Neurosci Bull       Date:  2019-01-04       Impact factor: 5.203

4.  Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: discovery by a proteomics approach.

Authors:  Jian-Ying Zhou; Leila Afjehi-Sadat; Seneshaw Asress; Duc M Duong; Merit Cudkowicz; Jonathan D Glass; Junmin Peng
Journal:  J Proteome Res       Date:  2010-10-01       Impact factor: 4.466

Review 5.  Applying proteomics to the diagnosis and treatment of ALS and related diseases.

Authors:  Robert Bowser; David Lacomis
Journal:  Muscle Nerve       Date:  2009-11       Impact factor: 3.217

Review 6.  Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations.

Authors:  Robert Bowser; Martin R Turner; Jeremy Shefner
Journal:  Nat Rev Neurol       Date:  2011-10-11       Impact factor: 42.937

7.  Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic.

Authors:  Nils von Neuhoff; Tonio Oumeraci; Thomas Wolf; Katja Kollewe; Peter Bewerunge; Boris Neumann; Benedikt Brors; Johannes Bufler; Ulrich Wurster; Brigitte Schlegelberger; Reinhard Dengler; Marc Zapatka; Susanne Petri
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

8.  Glycans in sera of amyotrophic lateral sclerosis patients and their role in killing neuronal cells.

Authors:  Meital Edri-Brami; Benyamin Rosental; Dana Hayoun; Michael Welt; Hila Rosen; Itzhak Wirguin; Beatrice Nefussy; Vivian E Drory; Angel Porgador; Rachel G Lichtenstein
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

Review 9.  Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Jared S Katzeff; Fiona Bright; Katherine Phan; Jillian J Kril; Lars M Ittner; Michael Kassiou; John R Hodges; Olivier Piguet; Matthew C Kiernan; Glenda M Halliday; Woojin Scott Kim
Journal:  Brain       Date:  2022-06-03       Impact factor: 15.255

10.  Beta-2 microglobulin is important for disease progression in a murine model for amyotrophic lateral sclerosis.

Authors:  Kim A Staats; Susann Schönefeldt; Marike Van Rillaer; Annelies Van Hoecke; Philip Van Damme; Wim Robberecht; Adrian Liston; Ludo Van Den Bosch
Journal:  Front Cell Neurosci       Date:  2013-12-10       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.